Klaricid contains clarithromycin, a bactericidal and bacteriostatic antibacterial agent, and is registered in 21 countries across Latin America, parts of Europe, and Asia. Markets where the brand is marketed include Japan, Brazil, Greece, Mexico, and Bangladesh — a footprint that brings Klaricid into regular contact with travellers and expatriates moving between these regions.
Clarithromycin is used in the management of a range of bacterial infections, with the registered indications for Klaricid covering respiratory tract infections such as bronchitis, pneumonia, and pharyngitis, as well as skin presentations and gastrointestinal use in the context of Helicobacter pylori-associated duodenal ulcer disease. The structured indication block further down this page lists the uses recognised by national regulators in each market where Klaricid is sold.
Because Klaricid is distributed in a mid-sized international footprint, travellers often encounter clarithromycin abroad either under the Klaricid brand or as a different clarithromycin-containing product. Regulatory packaging, prescription pathways, and brand names vary considerably between Latin American, European, and Asian markets, and a local pharmacist can usually confirm whether a clarithromycin product on the shelf corresponds to what was prescribed at home.
Other antibacterial agents with similar therapeutic positioning circulate worldwide under a range of active ingredients and brand names, although molecules within and adjacent to this class are not freely interchangeable — antibiotic selection depends on the specific infection, local resistance patterns, and individual patient factors. Anyone who has been prescribed Klaricid, is considering it, or is trying to identify a local equivalent abroad should make that decision together with a healthcare provider.
